var data={"title":"Porfimer: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Porfimer: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6805?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=porfimer-patient-drug-information\" class=\"drug drug_patient\">see &quot;Porfimer: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211474\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Photofrin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211475\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Photofrin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211499\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211478\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal cancer or endobronchial non-small cell lung cancer (photodynamic therapy):</b> IV: 2 mg/kg, followed by endoscopic exposure to the appropriate laser light and debridement; repeat courses must be separated by at least 30 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Barrett esophagus dysplasia (photodynamic therapy):</b> IV: 2 mg/kg, followed by endoscopic exposure to the appropriate laser light; repeat courses must be separated by at least 90 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211479\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448440\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use caution as porfimer elimination may be prolonged.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448441\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use caution as porfimer elimination may be prolonged.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211453\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Intravenous, as sodium [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Photofrin: 75 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211439\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186075\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Intravenous, as sodium [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Photofrin: 15 mg, 75 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211456\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer slow IV injection over 3 to 5 minutes. Avoid extravasation (if extravasation occurs, protect area from light and sunlight).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to the potential for photosensitivity reactions, wear rubber gloves and eye protection and avoid skin and eye contact during administration; if overexposure occurs, protect from bright light. Spills should be wiped with a damp cloth and contaminated material should be disposed of properly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211454\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Barrett esophagus dysplasia (photodynamic therapy):</b> Ablation of high-grade dysplasia in Barrett esophagus (in patients who do not undergo esophagectomy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endobronchial cancer (photodynamic therapy):</b> Treatment of microinvasive endobronchial non-small cell lung cancer (NSCLC) in patients for whom surgery and radiation therapy are not indicated; reduction of obstruction and symptom palliation in patients with obstructing (partial or complete) endobronchial NSCLC</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal cancer (photodynamic therapy):</b> Palliation of completely obstructing esophageal cancer, or partially obstructing esophageal cancer in patients who cannot be treated satisfactorily with Nd:YAG laser therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211446\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (8% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion (5% to 24%), pain (5% to 22%), insomnia (5% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin photosensitivity (19% to 69%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Esophageal stenosis (6% to 38%), nausea (24%), constipation (5% to 24%), abdominal pain (20%), vomiting (17%), dysphagia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (esophageal cancer: 32%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pleural effusion (5% to 32%), dyspnea (7% to 30%), bronchial obstruction (&le;21%; includes bronchial stenosis), bronchial plugs (&le;21%), pneumonia (12% to 18%), hemoptysis (16%; massive: 10%), cough (7% to 15%), bronchoconstriction (bronchostenosis: 11%), pharyngitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (16% to 31%), serous drainage (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation (10%), hypotension (7%), peripheral edema (5% to 7%), cardiac failure (esophageal carcinoma and endobronchial cancer: &le;7%), hypertension (6%), tachycardia (6%), edema (5%), substernal pain (5%), angina pectoris (&lt;5%), bradycardia (&lt;5%), myocardial infarction (&lt;5%), pulmonary embolism (&lt;5%), sick sinus syndrome (&lt;5%), supraventricular tachycardia (&lt;5%), thrombosis (pulmonary: &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (6% to 7%), voice disorder (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (9%), dehydration (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (8%), disease of esophagus (esophageal edema: 8%), hematemesis (8%), tracheoesophageal fistula (6%), dyspepsia (2% to 6%), diarrhea (5%), eructation (5%), esophagitis (5%), melena (5%), esophageal perforation (&lt;5%), gastric ulcer (&lt;5%), intestinal obstruction (&lt;5%), peritonitis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Tumor hemorrhage (8%), pulmonary hemorrhage (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Jaundice (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (9%), abscess (lung: &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Diplopia (&lt;5%), eye pain (&lt;5%), photophobia (&lt;5%), visual disturbance (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (&le;10%), respiratory insufficiency (5% to 10%), airway obstruction (including laryngotracheal edema: &lt;5%), bronchospasm (&lt;5%), pneumonitis (&lt;5%), pulmonary edema (&lt;5%), respiratory failure (&lt;5%), stridor (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Ulcer (bronchial: 9%), postoperative complication (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cataract, cerebrovascular accident, cutaneous nodule, disturbance in fluid balance, fragile skin, gastrointestinal disease (gastroesophageal fistula, gastroesophageal perforation), hemorrhage, hypertrichosis, infusion related reaction (including dizziness and urticaria), pseudoporphyria, sepsis, skin discoloration, thromboembolism, wrinkling of skin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211459\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porphyria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Photodynamic therapy (PDT) is contraindicated in patients with current tracheoesophageal or bronchoesophageal fistula; tumors eroding into a major blood vessel; emergency treatment of severe acute respiratory distress when caused by endobronchial lesion; esophageal or gastric varices; esophageal ulcers &gt;1 cm in diameter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i> Additional contraindications (not in US labeling): Hypersensitivity to porphyrins; photodynamic therapy is contraindicated in patients with papillary bladder cancer who have received prior total bladder radiation or whose functional bladder capacity is &lt;200 mL and in patients with coexisting bladder tumors of stage greater than stage 1 (T1) who have invasive cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211443\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Airway obstruction: Treatment-induced inflammation may obstruct airway. Use with caution in patients with endobronchial tumors, especially if in areas where main airway may be obstructed (long or surrounding tumors). Necrotic debris or mucositis may also cause airway obstruction. Monitor closely between laser therapy and debridement for respiratory distress; may require urgent bronchoscopy to remove secretions or debris.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chest pain: Inflammatory responses within the treatment area may result in substernal chest pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal strictures: Esophageal strictures may occur, usually within 6 months of treatment. May require multiple dilations to resolve. The risk is increased with nodule pretreatment or with re-treatment of the same area.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Avoid extravasation. If extravasation occurs, protect affected area from light; use of antidotes is of unknown benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastroesophageal fistula/perforation: Serious and potentially fatal gastrointestinal and esophageal necrosis and perforation may occur following treatment. Due to the high risk for fistula, do not use in patients with esophageal tumors eroding into the trachea or bronchial tree/wall. Use is contraindicated in patients with existing tracheoesophageal or bronchoesophageal fistula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Patients with esophageal varices or tumors eroding into pulmonary blood vessels are at increased risk for hemorrhage, including fatal massive pulmonary hemoptysis (FMH). Other risk factors for FMH include large, centrally-located tumors, cavitating tumors, or extensive tumor extrinsic to the bronchus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular photosensitivity: Ocular discomfort has been reported with sun or bright light exposure. For at least 30 days (and until ocular sensitivity resolves), when outdoors, patients should wear dark sunglasses which have an average white light transmittance of &lt;4%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Photosensitivity reactions are common in patients who are exposed to direct sunlight or bright indoor light (eg fluorescent lights, unshaded light bulbs, examination/operating lights). Conventional ultraviolet (UV) sunscreens are <b>not</b> protective against photosensitivity reactions caused by visible light. Photosensitivity may last 30 to 90 days or more. Encourage exposure to ambient indoor light (aids in gradually inactivating residual porfimer). Patients should be educated to test for residual photosensitivity before resuming exposure to sunlight. Re-exposure to general sunlight should be gradual (expose small area of skin [not the face] for 10 minutes, if no photosensitivity (eg, edema, erythema, blistering) occurs after 24 hours, may gradually resume normal outdoor activities; if photosensitivity occurs then wait 2 weeks and retest).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Thromboembolic events may occur, generally in patients with additional risk factors for thromboembolism (eg, advanced cancer, prolonged immobilization, cardiovascular disease, or following major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Barrett esophagus: In patients with Barrett esophagus, conduct rigorous surveillance (endoscopic biopsy every 3 months until 4 consecutive negative results for high-grade dysplasia followed by further follow-up per physician judgment). The long-term effects of photodynamic therapy in patients with Barrett esophagus is not known. Esophageal strictures are common adverse events associated with photodynamic therapy of Barrett esophagus; esophageal dilation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal/gastric varices: Not suited for treatment of patients with esophageal or gastric varices (due to the high risk for hemorrhage).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Elimination may be prolonged in hepatic impairment; toxicities may be increased. Photosensitivity may be increased beyond 90 days in patients with mild-to-severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Elimination may be prolonged in renal impairment; toxicities may be increased. Photosensitivity may be increased beyond 90 days in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitizing drugs: Concurrent use with other photosensitizing agents may increase the risk for photosensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Allow 2 to 4 weeks to elapse after phototherapy prior to initiating radiation therapy; 4 weeks should elapse after radiation therapy prior to initiating phototherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299910\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211448\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9791&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Photosensitizing Agents: May enhance the photosensitizing effect of Porfimer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211450\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211461\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13185708\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if porfimer is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to not administer porfimer treatment or to discontinue breast-feeding, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27259307\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor injection site during infusion (for extravasation); monitor in between laser and debridement for evidence of respiratory distress in patients with endobronchial tumors; monitor for signs/symptoms of photosensitivity, hemorrhage, thromboembolic events, gastroesophageal fistulas/perforation, esophageal strictures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211442\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Porfimer's cytotoxic activity is dependent on light and oxygen. Following administration, the drug is selectively retained in neoplastic tissues. Exposure of the drug to laser light at wavelengths &gt;630 nm results in the production of oxygen free-radicals. Release of thromboxane A<sub>2</sub>, leading to vascular occlusion and ischemic necrosis, may also occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211458\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 0.49 &plusmn; 0.28 L/kg (Pereira 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: First dose: 17 days; Second dose: 30 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323709\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Photofrin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (1): $24,512.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211462\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Photobarr (CZ, EE, HU, MT, RO);</li>\n      <li>Photofrin (AR, BB, BG, CR, DE, DO, FI, FR, GB, GR, GT, HN, HU, IL, JP, NI, NL, PA, PL, PT, SE, SV, TW, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Overholt BF, Wang KK, Burdick JS, et al, &ldquo;Five-Year Efficacy and Safety of Photodynamic Therapy With Photofrin in Barrett's High-Grade Dysplasia,&rdquo; <i>Gastrointest Endosc</i>, 2007, 66(3):460-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/porfimer-drug-information/abstract-text/17643436/pubmed\" target=\"_blank\" id=\"17643436\">17643436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira SP, Ayaru L, Ackroyd R, et al, &ldquo;The Pharmacokinetics and Safety of Porfimer After Repeated Administration 30-45 Days Apart to Patients Undergoing Photodynamic Therapy,&rdquo; <i>Aliment Pharmacol Ther</i>, 2010, 32(6):821-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/porfimer-drug-information/abstract-text/20629974/pubmed\" target=\"_blank\" id=\"20629974\">20629974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Photofrin (porfimer) [prescribing information]. Bannockburn, IL: Pinnacle Biologics; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Photofrin (porfimer) [Canadian product monograph]. St Michael, Barbados: Concordia Laboratories Inc: October 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9791 Version 95.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211474\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F211475\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F211499\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211478\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F211479\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22448440\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22448441\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211453\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F211439\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13186075\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211456\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211454\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211446\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211459\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211443\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299910\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211448\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F211450\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211461\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13185708\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27259307\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211442\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211458\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323709\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F211462\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9791|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=porfimer-patient-drug-information\" class=\"drug drug_patient\">Porfimer: Patient drug information</a></li></ul></div></div>","javascript":null}